Recurrent and new hepatitis C virus infection after liver transplantation

James E. Evermart, Yuling Wei, Heather Eng, Michael R. Charlton, David H. Persing, Russell H. Wiesner, Jeffrey J. Germer, John R. Lake, Rowen K. Zetterman, Jay H. Hoofnagle

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Chronic infection with the hepatitis C virus (HCV) is the most common reason for liver transplantation. We examined the results of laboratory tests for HCV on a cohort of patients who received a liver transplant between 1990 and 1994 at three large centers. Seven hundred twenty-two recipients and 604 donors were tested for antibody to HCV (anti-HCV) using a second-generation enzyme-linked immunoassay (EIA-2), followed by recombinant immunoblot (RIBA- 2) and HCV RNA confirmation by reverse-transcription polymerase chain reaction (RT-PCR) (with genotyping and viral quantification). Diagnosis of posttransplantation infection required detection of serum HCV RNA that could be genotyped by sequencing or was repeatedly positive despite being unsequenceable. Twenty-five percent of transplantation candidates were seropositive for anti-HCV. Approximately 86% of anti-HCV-positive, 93% of RIBApositive, and 97% of HCV RNA-positive candidates developed infection after transplantation. Pretransplantation HCV RNA was superior to RIBA-2 for predicting posttransplantation infection. Whereas HCV genotype was identified in nearly all candidates and changed little after transplantation, serum viral levels rose markedly after transplantation. Fifteen donors were either anti-HCV- or HCV RNA-positive. Recipients of grafts from donors with HCV RNA all developed infection, whereas infection was not detected in recipients of grafts from donors with anti-HCV but without detectable HCV RNA. The rate of new infection fell significantly (P = .02) after the introduction of EIA-2 screening of blood. Donor and candidate markers for HCV predict posttransplantation infection.

Original languageEnglish (US)
Pages (from-to)1220-1226
Number of pages7
JournalHepatology
Volume29
Issue number4
StatePublished - 1999

Fingerprint

Virus Diseases
Hepacivirus
Liver Transplantation
Hepatitis C Antibodies
RNA
Infection
Tissue Donors
Transplantation
Transplants
Serum
Immunoenzyme Techniques
Reverse Transcription
Genotype
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Hepatology

Cite this

Evermart, J. E., Wei, Y., Eng, H., Charlton, M. R., Persing, D. H., Wiesner, R. H., ... Hoofnagle, J. H. (1999). Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology, 29(4), 1220-1226.

Recurrent and new hepatitis C virus infection after liver transplantation. / Evermart, James E.; Wei, Yuling; Eng, Heather; Charlton, Michael R.; Persing, David H.; Wiesner, Russell H.; Germer, Jeffrey J.; Lake, John R.; Zetterman, Rowen K.; Hoofnagle, Jay H.

In: Hepatology, Vol. 29, No. 4, 1999, p. 1220-1226.

Research output: Contribution to journalArticle

Evermart, JE, Wei, Y, Eng, H, Charlton, MR, Persing, DH, Wiesner, RH, Germer, JJ, Lake, JR, Zetterman, RK & Hoofnagle, JH 1999, 'Recurrent and new hepatitis C virus infection after liver transplantation', Hepatology, vol. 29, no. 4, pp. 1220-1226.
Evermart JE, Wei Y, Eng H, Charlton MR, Persing DH, Wiesner RH et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology. 1999;29(4):1220-1226.
Evermart, James E. ; Wei, Yuling ; Eng, Heather ; Charlton, Michael R. ; Persing, David H. ; Wiesner, Russell H. ; Germer, Jeffrey J. ; Lake, John R. ; Zetterman, Rowen K. ; Hoofnagle, Jay H. / Recurrent and new hepatitis C virus infection after liver transplantation. In: Hepatology. 1999 ; Vol. 29, No. 4. pp. 1220-1226.
@article{4b7a89cddf4e4bffb52362d0aad6ac56,
title = "Recurrent and new hepatitis C virus infection after liver transplantation",
abstract = "Chronic infection with the hepatitis C virus (HCV) is the most common reason for liver transplantation. We examined the results of laboratory tests for HCV on a cohort of patients who received a liver transplant between 1990 and 1994 at three large centers. Seven hundred twenty-two recipients and 604 donors were tested for antibody to HCV (anti-HCV) using a second-generation enzyme-linked immunoassay (EIA-2), followed by recombinant immunoblot (RIBA- 2) and HCV RNA confirmation by reverse-transcription polymerase chain reaction (RT-PCR) (with genotyping and viral quantification). Diagnosis of posttransplantation infection required detection of serum HCV RNA that could be genotyped by sequencing or was repeatedly positive despite being unsequenceable. Twenty-five percent of transplantation candidates were seropositive for anti-HCV. Approximately 86{\%} of anti-HCV-positive, 93{\%} of RIBApositive, and 97{\%} of HCV RNA-positive candidates developed infection after transplantation. Pretransplantation HCV RNA was superior to RIBA-2 for predicting posttransplantation infection. Whereas HCV genotype was identified in nearly all candidates and changed little after transplantation, serum viral levels rose markedly after transplantation. Fifteen donors were either anti-HCV- or HCV RNA-positive. Recipients of grafts from donors with HCV RNA all developed infection, whereas infection was not detected in recipients of grafts from donors with anti-HCV but without detectable HCV RNA. The rate of new infection fell significantly (P = .02) after the introduction of EIA-2 screening of blood. Donor and candidate markers for HCV predict posttransplantation infection.",
author = "Evermart, {James E.} and Yuling Wei and Heather Eng and Charlton, {Michael R.} and Persing, {David H.} and Wiesner, {Russell H.} and Germer, {Jeffrey J.} and Lake, {John R.} and Zetterman, {Rowen K.} and Hoofnagle, {Jay H.}",
year = "1999",
language = "English (US)",
volume = "29",
pages = "1220--1226",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Recurrent and new hepatitis C virus infection after liver transplantation

AU - Evermart, James E.

AU - Wei, Yuling

AU - Eng, Heather

AU - Charlton, Michael R.

AU - Persing, David H.

AU - Wiesner, Russell H.

AU - Germer, Jeffrey J.

AU - Lake, John R.

AU - Zetterman, Rowen K.

AU - Hoofnagle, Jay H.

PY - 1999

Y1 - 1999

N2 - Chronic infection with the hepatitis C virus (HCV) is the most common reason for liver transplantation. We examined the results of laboratory tests for HCV on a cohort of patients who received a liver transplant between 1990 and 1994 at three large centers. Seven hundred twenty-two recipients and 604 donors were tested for antibody to HCV (anti-HCV) using a second-generation enzyme-linked immunoassay (EIA-2), followed by recombinant immunoblot (RIBA- 2) and HCV RNA confirmation by reverse-transcription polymerase chain reaction (RT-PCR) (with genotyping and viral quantification). Diagnosis of posttransplantation infection required detection of serum HCV RNA that could be genotyped by sequencing or was repeatedly positive despite being unsequenceable. Twenty-five percent of transplantation candidates were seropositive for anti-HCV. Approximately 86% of anti-HCV-positive, 93% of RIBApositive, and 97% of HCV RNA-positive candidates developed infection after transplantation. Pretransplantation HCV RNA was superior to RIBA-2 for predicting posttransplantation infection. Whereas HCV genotype was identified in nearly all candidates and changed little after transplantation, serum viral levels rose markedly after transplantation. Fifteen donors were either anti-HCV- or HCV RNA-positive. Recipients of grafts from donors with HCV RNA all developed infection, whereas infection was not detected in recipients of grafts from donors with anti-HCV but without detectable HCV RNA. The rate of new infection fell significantly (P = .02) after the introduction of EIA-2 screening of blood. Donor and candidate markers for HCV predict posttransplantation infection.

AB - Chronic infection with the hepatitis C virus (HCV) is the most common reason for liver transplantation. We examined the results of laboratory tests for HCV on a cohort of patients who received a liver transplant between 1990 and 1994 at three large centers. Seven hundred twenty-two recipients and 604 donors were tested for antibody to HCV (anti-HCV) using a second-generation enzyme-linked immunoassay (EIA-2), followed by recombinant immunoblot (RIBA- 2) and HCV RNA confirmation by reverse-transcription polymerase chain reaction (RT-PCR) (with genotyping and viral quantification). Diagnosis of posttransplantation infection required detection of serum HCV RNA that could be genotyped by sequencing or was repeatedly positive despite being unsequenceable. Twenty-five percent of transplantation candidates were seropositive for anti-HCV. Approximately 86% of anti-HCV-positive, 93% of RIBApositive, and 97% of HCV RNA-positive candidates developed infection after transplantation. Pretransplantation HCV RNA was superior to RIBA-2 for predicting posttransplantation infection. Whereas HCV genotype was identified in nearly all candidates and changed little after transplantation, serum viral levels rose markedly after transplantation. Fifteen donors were either anti-HCV- or HCV RNA-positive. Recipients of grafts from donors with HCV RNA all developed infection, whereas infection was not detected in recipients of grafts from donors with anti-HCV but without detectable HCV RNA. The rate of new infection fell significantly (P = .02) after the introduction of EIA-2 screening of blood. Donor and candidate markers for HCV predict posttransplantation infection.

UR - http://www.scopus.com/inward/record.url?scp=0032924021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032924021&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 1220

EP - 1226

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 4

ER -